Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23728205 | 0.97 | HPGD (0.54) | HPGDTSHRHRH3FKBP1AALDH1A1 | |
| SCHEMBL8898022 | 0.86 | L3MBTL1 (0.64) | HPGDHRH3ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL8896530 | 0.86 | ALDH1A1 (0.58) | ALDH1A1LMNASMN1; SMN2KCNJ1MEN1 | |
| SCHEMBL8897735 | 0.84 | SMN1; SMN2 (0.57) | HPGDTSHRHRH3ALDH1A1LMNA | |
| SCHEMBL4428749 | 0.81 | ALDH1A1 (0.60) | HPGDTSHRALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL5650248 | 0.77 | HTT (0.46) | HRH3ALDH1A1LMNAKCNJ1KCNH2 | |
| SCHEMBL14405008 | 0.77 | HTT (0.46) | HRH3ALDH1A1LMNAKCNJ1KCNH2 | |
| SCHEMBL4185130 | 0.77 | HTT (0.46) | HRH3ALDH1A1LMNAKCNJ1KCNH2 | |
| SCHEMBL28644232 | 0.77 | TSHR (0.62) | HPGDTSHRALDH1A1L3MBTL1KMT2A | |
| SCHEMBL17676780 | 0.77 | ALDH1A1 (0.46) | HRH3ALDH1A1LMNASMN1; SMN2KCNJ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108440452-A | A kind of key intermediate 1- of almotriptan（4- amino-benzyl sulfonyls）The preparation method of pyrrolidines | 嘉兴市第二医院 | 2018-08-24 | — | — | CN | claimed |
| CN-108440452-A | A kind of key intermediate 1- of almotriptan（4- amino-benzyl sulfonyls）The preparation method of pyrrolidines | 嘉兴市第二医院 | 2018-08-24 | — | — | CN | disclosed |
| US-20150352108-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON | ALZHEIMER'S INSTITUTE OF AMERICA (US) | 2015-12-10 | — | — | US | disclosed |
| US-20120238540-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 | MYREXIS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| EP-2488503-A1 | AMINO - PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBKL AND/OR IKK EPSILON | Myrexis, Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| WO-2011046970-A1 | AMINO - PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBKL AND/OR IKK EPSILON | MYREXIS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| EP-2081893-B1 | SUBSTITUTED INDOLES | AUSPEX PHARMACEUTICALS INC (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2081893-A2 | SUBSTITUTED INDOLES | Auspex Pharmaceuticals, Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20080103189-A1 | PREPARATION AND UTILITY OF SUBSTITUTED INDOLES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103189-A1 | PREPARATION AND UTILITY OF SUBSTITUTED INDOLES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103189-A1 | PREPARATION AND UTILITY OF SUBSTITUTED INDOLES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| WO-2008049116-A2 | SUBSTITUTED INDOLES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103189-A1 | PREPARATION AND UTILITY OF SUBSTITUTED INDOLES | IDO1, TPH1, IDO2 | HPGD 282/4885TSHR 1484/4885HRH3 838/4885 |
| US-20150352108-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON | TBK1, NFKBIA, CHUK | HPGD 1949/4885TSHR 4513/4885HRH3 3651/4885 |
| US-20120238540-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 | TBK1, NFKBIA, IKBKB | HPGD 2881/4885TSHR 4688/4885HRH3 3418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.